In short
This article explores a clinical trial investigating the use of Calcium Chloride Hexahydrate in combination with other treatments for patients with metastatic colorectal cancer. The study aims to evaluate the effectiveness and safety of calcium electroporation (Ca-EP) performed alongside irreversible electroporation (IRE) and immunotherapy using pembrolizumab. This innovative approach seeks to improve outcomes for patients with advanced colorectal cancer who have limited treatment options.
At a glance
- Study Type
- Phase 2 clinical trial
- Main Objective
- Evaluate efficacy and safety of Ca-EP with IRE followed by pembrolizumab
- Target Population
- Adults with stage IV, non-resectable pMMR colorectal cancer
- Key Inclusion Criteria
- Age ≥18, adequate organ function, at least two metastatic tumors
- Key Exclusion Criteria
- Prior immune checkpoint inhibitor treatment, certain cardiac conditions
- Primary Endpoint
- Safety and tolerability of the combination therapy
- Secondary Endpoints
- Systemic response, tumor response, survival outcomes, quality of life
- Calcium Chloride Hexahydrate Usage
- Maximum 3 millimoles daily dose, 1-day treatment period
What is Calcium Chloride Hexahydrate?
Calcium Chloride Hexahydrate is a chemical compound that contains calcium, chloride, and water molecules. In the medical context, it is being studied as part of a new treatment approach for patients with advanced colorectal cancer. This compound is used in a procedure called calcium electroporation (Ca-EP), which is combined with other treatments to potentially improve outcomes for cancer patients.
Treatment Approach
The treatment approach being studied combines several methods:
- Calcium Electroporation (Ca-EP): This technique involves injecting calcium chloride hexahydrate into the tumor and then applying electrical pulses. This process helps to increase the amount of calcium inside cancer cells, which can lead to cell death.
- Irreversible Electroporation (IRE): This is a technique that uses electrical pulses to create permanent openings in cell membranes, leading to cell death.
- Immunotherapy: After the Ca-EP and IRE procedures, patients receive a drug called pembrolizumab. This is a type of immunotherapy that helps the body's immune system recognize and attack cancer cells.
This combination approach aims to not only directly attack the tumor but also stimulate the body's immune response against cancer cells throughout the body.
Target Patient Group
This treatment is being studied for patients with:
- Stage IV colorectal cancer: This means the cancer has spread from the colon or rectum to other parts of the body.
- pMMR tumors: This refers to tumors with proficient mismatch repair, a characteristic that can make some cancers less responsive to certain treatments.
- Cancer that has not responded to, or the patient cannot tolerate, standard chemotherapy options.
Potential Benefits
The researchers hope this treatment approach could offer several benefits:
- Improved effectiveness against advanced colorectal cancer.
- Stimulation of the body's immune response against cancer cells.
- Potential to treat tumors that haven't responded to other therapies.
- Possible improvement in survival rates and quality of life for patients.
Safety Considerations
As with any medical treatment, there are important safety considerations:
- The treatment is not suitable for patients with certain heart conditions, epilepsy, or specific autoimmune diseases.
- Patients need to have adequate kidney, liver, and bone marrow function to be eligible for the treatment.
- The treatment may affect fertility, so patients of reproductive age need to use contraception during and after treatment.
Ongoing Research
A clinical trial is currently underway to study this treatment approach. The researchers are looking at several aspects:
- How safe and tolerable the treatment is for patients.
- How effective the treatment is at fighting the cancer.
- How the treatment affects the immune system's response to the cancer.
- How long patients live without their cancer getting worse (progression-free survival).
- How long patients survive overall.
- How the treatment affects patients' quality of life.
It's important to note that this is a Phase II study, which means the treatment is still in the research phase and is not yet approved for general use. The results of this study will help determine if this approach could become a new treatment option for patients with advanced colorectal cancer in the future.